Prevalence of restless legs syndrome (RLS) and efficacy of pramipexole on RLS in type 2 diabetes

Prevalence of restless legs syndrome (RLS) and efficacy of pramipexole on RLS in type 2 diabetes - Restless legs syndrome and type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008347

Enrollment

100

Registered

2012-07-04

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

pramipexole

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. type 2 diabetes 2. aged; 20 years 3. diabetes duration; 1 year.

Exclusion criteria

Exclusion criteria: 1. type 1 diabetes 2. secondary diabetes 3. alcoholism 4. severe depression or severe psychological condition 5. malignancy 6.severe renal dysfunction or dialysis; anemia; and rheumatoid arthritis

Design outcomes

Primary

Measure	Time frame
Improvement in International Restless Legs Syndrome Rating Scale (IRLS)	—

Secondary

Measure	Time frame
Improvement in Pittsburgh Sleep Quality Index (PSQI)	—

Countries

Japan

Contacts

Public ContactShinichi Harashima

Kyoto University Department of Diabetes and Clinical Nutrition

harasima@metab.kuhp.kyoto-u.ac.jp075-751-3560

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026